Phase 3 Macular Oedema Clinical Trials
4 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–4 of 4 trials
Recruiting
Phase 3
Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns
Severe Diabetic Macular Oedema
Belfast Health and Social Care Trust264 enrolled22 locationsNCT06985706
Active
Phase 3
Comparing the effectiveness and safety of two treatments (OZURDEX® intravitreal implant versus Avastin®) for diabetic eye disease in adult Indigenous patients living in Western Australia.
Diabetic Macular Oedema
LIONS EYE INSTITUTE LTD50 enrolled1 locationACTRN12618000202268
Completed
Phase 2Phase 3
Open Label Extension of a Clinical Trial of Intravitreal Triamcinolone for Diabetic Macular Oedema (TDMX study)
Diabetic Macular Oedema
Professor Mark Gillies64 enrolled1 locationACTRN12605000244606
Completed
Phase 2Phase 3
Intravitreal Triamcinolone for Clinically Significant Diabetic Macular Oedema that Persists after Laser Treatment (TDMO)
Diabetic Macular Oedema
Professor Mark Gillies70 enrolled1 locationACTRN12605000211662